A 32-year-old woman at 6 weeks of gestation presents with a severe depressive episode and suicidal ideation. She has a 10-year history of bipolar disorder, previously well-controlled on lithium carbonate 900 mg daily. Her psychiatrist is concerned about continuing lithium in pregnancy due to known teratogenic risks. Which of the following statements regarding lithium use in pregnancy is MOST ACCURATE?

Explanation

## Lithium in Pregnancy: Risk-Benefit Assessment **Key Point:** Lithium is a known teratogen with a documented association with cardiac malformations (Ebstein's anomaly), but complete discontinuation may pose severe maternal psychiatric risks. The decision requires careful risk-benefit analysis and close fetal monitoring. ### Teratogenic Effects of Lithium **First Trimester Exposure:** - **Cardiac malformations:** Ebstein's anomaly (tricuspid valve dysplasia) — relative risk 10–20× higher than general population - Incidence: ~1 in 1000 to 1 in 2000 exposed pregnancies (vs. 1 in 20,000 in general population) - Other cardiac defects: atrial septal defect (ASD), ventricular septal defect (VSD), patent foramen ovale (PFO) - **Renal effects:** Nephrogenic diabetes insipidus, polyhydramnios (more common in 2nd/3rd trimester) - **CNS effects:** Goiter, hypothyroidism, developmental delay ### Risk-Benefit Framework in Lithium-Dependent Pregnancy | Scenario | Recommendation | Rationale | |---|---|---| | **Severe bipolar disorder with suicidal risk** | Continue lithium with dose reduction & monitoring | Maternal suicide risk > fetal teratogenic risk | | **Mild-moderate depression, first episode** | Discontinue or switch to safer agent (sertraline, paroxetine) | Lower maternal psychiatric risk; alternative agents available | | **Already on lithium at conception** | Counseling + fetal echocardiography at 16–20 weeks | Assess risk vs. benefit; do not abruptly stop | | **Planned pregnancy on lithium** | Preconception counseling; consider switching to safer agent | Allows time for medication transition | **High-Yield:** The absolute teratogenic risk of lithium is **not negligible but not absolute**—approximately 1–2% of exposed pregnancies develop cardiac malformations (vs. 0.05% baseline). However, maternal psychiatric decompensation and suicide risk in untreated bipolar disorder is much higher. ### Management Strategy in This Case 1. **Dose reduction:** Decrease lithium to 600–750 mg daily (lower therapeutic levels: 0.4–0.8 mEq/L) 2. **Frequent monitoring:** Lithium levels every 2–4 weeks (pregnancy increases renal clearance) 3. **Fetal assessment:** High-resolution fetal echocardiography at 16–20 weeks to detect cardiac malformations 4. **Thyroid & renal function:** Monitor maternal TSH and creatinine; assess fetal urine output (polyhydramnios screening) 5. **Psychiatric support:** Close liaison with psychiatry; consider adjunctive psychotherapy 6. **Postpartum planning:** Lithium can be restarted at pre-pregnancy dose after delivery; breastfeeding generally avoided (lithium in breast milk) **Clinical Pearl:** Abrupt discontinuation of lithium in a woman with severe bipolar disorder carries a **60–70% risk of relapse** within the first year. This relapse risk often exceeds the teratogenic risk of lithium exposure, especially in the first trimester. **Mnemonic:** **LITHIUM in pregnancy = Limited dose, Intense monitoring, Trimester-specific counseling, Heart echo at 16–20 weeks, Informed choice, Urgent psychiatric liaison, Manage postpartum carefully** ### Why Other Options Are Wrong - **Option 0 (Absolute contraindication):** Oversimplifies the risk-benefit analysis; abrupt cessation in severe bipolar disorder poses greater maternal and fetal risk. - **Option 2 (Safe in 1st trimester only):** Incorrect; cardiac malformations occur specifically with 1st trimester exposure; 2nd/3rd trimester risks are different (polyhydramnios, nephrogenic DI). - **Option 3 (No teratogenic effects):** Factually wrong; Ebstein's anomaly association is well-established. [cite:Harrison 21e Ch 314; KD Tripathi 8e Ch 21]